Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Total 11685 results

National Cancer Institute (NCI)

Completed

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States, Singapore
National Cancer Institute (NCI)

Terminated

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NSCLC

Germany
G1 Therapeutics, Inc.

Recruiting

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer

Spain, Greece, Turkey, Poland, Georgia, Austria, Belgium, Bulgaria, Germany, Hungary
Istituto Scientifico Romagnolo per lo Studio e...
Agenzia Italiana del Farmaco

Unknown

CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (KENDO)

Metastatic Breast Cancer | Hormone Receptor Positive Breast Cancer | Hormone Receptor Negative Breast Cancer

Italy
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
Samsung Medical Center

Completed

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Non-small Cell Lung Cancer
European Organisation for Research and Treatment...

Suspended

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (REMNANT)

Non Small Cell Lung Cancer
Central South University

Recruiting

Hepatotoxicity Related to Protein Kinase Inhibitors

Cancer

China
Universitätsklinikum Hamburg-Eppendorf
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Refractory Cancer

Germany
Assiut University

Not yet recruiting

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

CML, Chronic Phase
Xiuning Le
M.D. Anderson Cancer Center; Eli Lilly and Company

Active, not recruiting

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | EGFR Gene Mutation

United States
Alimentiv Inc.
Alimentiv Translational Research Consortium

Terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC)

Ulcerative Colitis

Netherlands
Massachusetts General Hospital
Tesaro, Inc.

Recruiting

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Lung Cancer

United States
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
National Cancer Institute (NCI)

Completed

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Epithelioid Mesothelioma | Cholangiocarcinoma, Extrahepatic | Neoplasms With Mesothelin Expression | Adenocarcinoma, Pancreatic

United States
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Institute of Cancer Research, United Kingdom

Active, not recruiting

Stereotactic Body Radiotherapy for the Treatment of OPD (HALT)

NSCLC

United Kingdom, France, Switzerland, Italy, Spain
Vanderson Geraldo Rocha

Terminated

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 (RUXO-COVID)

SARS-CoV2 | Severe Acute Respiratory Syndrome Coronavirus 2

Brazil
Leiden University Medical Center
Galapagos NV

Recruiting

JAK Inhibition in Ulcerative Colitis

Colitis, Ulcerative

Netherlands
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Bayer

Completed

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Solid Cancer

Germany, Italy, United States, Japan, United Kingdom
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer; National Comprehensive Cancer Network

Completed

A Study of Axitinib in Advanced Carcinoid Tumors

Carcinoid Tumor

United States
Shanghai East Hospital

Active, not recruiting

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

Acneiform Eruptions

China
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
Novartis Pharmaceuticals

Active, not recruiting

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)

Chronic Myeloid Leukemia

Italy
H. Lee Moffitt Cancer Center and Research Institute
National Heart, Lung, and Blood Institute (NHLBI); CTI BioPharma

Completed

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

GVHD | Graft Vs Host Disease

United States
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Incyte Corporation

Terminated

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19

United States, Russian Federation
Anwaar Saeed
AstraZeneca; Exelixis

Active, not recruiting

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Kami Maddocks, MD

Active, not recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory/Relapsed Chronic Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
Sameek Roychowdhury

Active, not recruiting

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Malignant Neoplasm

United States
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
Lisa Barrett
Nova Scotia Health Authority; Dalhousie University

Active, not recruiting

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

COVID-19

Canada
AIO-Studien-gGmbH
Boehringer Ingelheim

Terminated

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer (MARBLE)

Non-small-cell Lung Cancer With Somatic EGFR Mutations

Germany
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Dermatomyositis, Adult Type

China
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Moderate-Severe Chronic Graft Versus Host Disease

United States
Liga Panamericana de Asociaciones de Reumatologia...

Recruiting

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors (PREJAK)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis

Argentina
University Hospital Muenster
Boehringer Ingelheim

Unknown

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Germany
Jonsson Comprehensive Cancer Center
AstraZeneca

Recruiting

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Secondary Central Nervous System Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation; H. Jean Khoury Cure CML Consortium

Recruiting

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada, Australia, Puerto Rico
University of Rochester

Terminated

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Esophageal Cancer

United States
Barbara Ann Karmanos Cancer Institute
AstraZeneca

Withdrawn

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations